Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Past Issue Archives
Interactive:
Self-Assessment Questions
Review of
Clinical Signs
Clinical Review
Quiz
Pediatric Rounds
Resident Grand Rounds
Article Archives
Case Reports
Clinical Practice
Exams
Pediatric Rounds
Resident Grand Rounds
Review of
Clinical Signs

Guide to Reading
Hospital Physician
Editorial Board
Information for Authors

Reprints, Permissions, & Copyright
Site Map
Self-Assessment Questions

Emergency Medicine


Answer 2
  1. EGDT. This patient has severe sepsis. Sepsis is defined by the presence of an infection and the systemic inflammatory response syndrome (eg, hyper/hypothermia, heart rate > 90 bpm, tachypnea, altered mental status, leukocytosis/leukopenia/bandemia, or elevated C-reactive protein or procalcitonin levels).² Severe sepsis is sepsis plus the presence of organ dysfunction or evidence of tissue hypoperfusion (serum lactate > 4 mmol/L). EGDT consists of administering IV fluids, vasopressors, packed red blood cells, and inotropic agents to target a central venous pressure of 8 to 12 mm Hg, a mean arterial pressure of 65 to 90 mm Hg, and a central venous oxygen saturation of greater than 70% within 6 hours of identification.³ EGDT reduced absolute mortality by 16.5% in patients with severe sepsis or septic shock compared with standard therapy in a single-center randomized trial.&sup4; Similar mortality reductions have been found in other studies using historical controls or comparing actual mortality with predicted mortality using APACHE II scores.&sup5; Corticosteroids have been shown to reduce mortality in patients with vasopressor-dependent septic shock, in those requiring mechanical ventilation, and in those who fail a cosyntropin stimulation test. However, this finding has recently been disputed in a large trial not yet published. Recombinant-activated protein C, an endogenous anticoagulant with anti-inflammatory properties, has been shown to reduce mortality in patients with an APACHE II score of 25 or more, sepsis-induced multiorgan failure, septic shock, or sepsis-induced acute respiratory distress syndrome who have no absolute contraindication related to bleeding risk (including a hemorrhagic stroke within 3 months, as in this patient). Elevated procalcitonin levels may be sensitive markers of bacterial sepsis, but procalcitonin has no therapeutic role. Protective ventilation strategies using low tidal volumes (6 mL/kg) have been associated with a reduction in mortality.

REFERENCES
2. Levy MM, Fink MP, Marshall JC, et al; SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:12506

3. Dellinger RP, Carlet JM, Masur H, et al; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [published errata appear in Crit Care Med 2004;32:1448 and 2004;32:216970]. Crit Care Med 2004;32: 85873.

4. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:136877.

5. Otero RM, Nguyen HB, Huang DT, et al. Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest 2006;130:157995.

Click here to return to the questions

 

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2009, Turner White Communications
Updated 2/25/08 • nvf